secwatch / observer
8-K filed July 27, 2023, 7:59 PM ET ticker ALLR CIK 0001860657
leadership confidence high sentiment neutral materiality 0.55

Allarity adds Benjamin, Oliver, Vazzano as directors; cures Nasdaq compliance gap

Allarity Therapeutics, Inc.

item 3.01item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Joe Vazzano

Director
ALLR · Allarity Therapeutics, Inc.
Effective
2023-08-01
Filed
July 27, 2023, 7:59 PM ET
Class I Director: Mr. Joe Vazzano, whose term will expire at the Company’s 2026 annual meeting of stockholders or until his respective successors are duly elected and qualified.
Departed

David Roth

Director
ALLR · Allarity Therapeutics, Inc.
Effective
2023-07-21
Filed
July 27, 2023, 7:59 PM ET
On July 21, 2023, the Board of the Company received the resignation of Dr. David Roth as director of the Company, effective immediately.
Appointed

Robert Oliver

Director
ALLR · Allarity Therapeutics, Inc.
Effective
2023-08-01
Filed
July 27, 2023, 7:59 PM ET
Class III Director: Mr. Robert Oliver, whose term will expire at the Company’s 2025 annual meeting of stockholders or until his respective successors are duly elected and qualified.
Appointed

Laura Benjamin

Director
ALLR · Allarity Therapeutics, Inc.
Effective
2023-08-01
Filed
July 27, 2023, 7:59 PM ET
Class II Director: Dr. Laura Benjamin, whose term will expire at the Company’s 2024 annual meeting of stockholders or until her respective successors are duly elected and qualified.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joe Vazzano was appointed as Director at Allarity Therapeutics, Inc..

Action
appointed
Role
Director
Exact text from the filing
Class I Director: Mr. Joe Vazzano, whose term will expire at the Company’s 2026 annual meeting of stockholders or until his respective successors are duly elected and qualified.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

David Roth resigned as Director at Allarity Therapeutics, Inc..

Action
resigned
Role
Director
Exact text from the filing
On July 21, 2023, the Board of the Company received the resignation of Dr. David Roth as director of the Company, effective immediately.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Oliver was appointed as Director at Allarity Therapeutics, Inc..

Action
appointed
Role
Director
Exact text from the filing
Class III Director: Mr. Robert Oliver, whose term will expire at the Company’s 2025 annual meeting of stockholders or until his respective successors are duly elected and qualified.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Laura Benjamin was appointed as Director at Allarity Therapeutics, Inc..

Action
appointed
Role
Director
Exact text from the filing
Class II Director: Dr. Laura Benjamin, whose term will expire at the Company’s 2024 annual meeting of stockholders or until her respective successors are duly elected and qualified.
View on SEC.gov

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001213900-23-060254
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.